Bioavailability profile of uceris®MMX extended-release tablets compared with entocort EC capsules in healthy volunteers

Journal of International Medical Research

Volumn 41, Issue 2, 2013, Pages 386-394

  Nicholls, Andrew ^a   Harris Collazo, Raúl ^b   Huang, Michael ^b   Hardiman, Yun ^b   Jones, Richard ^c   Moro, Luigi ^c  

^a Pharmaceutical Consulting   (United States)

^b Santarus Inc   (United States)

^c Cosmo Technologies Ltd ^*  (Ireland)

Author keywords

Bioavailability; Bioequivalence; Budesonide; Ulcerative colitis

Indexed keywords

BUDESONIDE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; SINGLE DRUG DOSE; TABLET; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 84878375674     PISSN: 03000605     EISSN: 14732300     Source Type: Journal    
DOI: 10.1177/0300060513476588     Document Type: Article

References (17)

1. D'Arienzo A, Panarese A, D'Armiento FP, et al. 5-Aminosalicylic acid suppositories in the maintenance of remission in idiopathic proctitis or proctosigmoiditis: a double-blind placebo-controlled clinical trial. Am J Gastroenterol 1990; 85: 1079-1082.
2. Marshall JK and Irvine EJ. Rectal aminosalicylate therapy for distal ulcerative colitis: a meta-analysis. Aliment Pharmacol Ther 1995; 9: 293-300.
3. Navarro F and Hanauer SB. Treatment of inflammatory bowel disease: safety and tolerability issues. Am J Gastroenterol 2003; 98(suppl): S18-S23.
4. Edsbäcker S, Andersson P, Lindberg C, et al. Liver metabolism of budesonide in rat, mouse, and man. Comparative aspects. Drug Metab Dispos 1987; 15: 403-411.
5. McKeage K and Goa KL. Budesonide (Entocort® EC Capsules): a review of its therapeutic use in the management of active Crohn's disease in adults. Drugs 2002; 62: 2263-2282.
6. Brattsand R. Overview of newer glucocorticosteroid preparations for inflammatory bowel disease. Can J Gastroenterol 1990; 4: 407-414.
7. Dahlström K, Edsbäcker S and Källén A. Rectal pharmacokinetics of budesonide. Eur J Clin Pharmacol 1996; 49: 293-298.
8. Löfberg R, Østergaard Thomsen O, Langholz E, et al. Budesonde versus prednisolone retention enemas in active distal ulcerative colitis. Aliment Pharmacol Ther 1994; 8: 623-629.
9. Löfberg R. New data on inflammatory bowel disease treatment with topical steroids. Research and Clinical Forums 1998; 20: 179-188.
10. Klotz U. Pharmacokinetic data for different 5-aminosalicylic acid and budesonide preparations. Med Klin (Munich) 1999; 94(suppl 1): 16-22. [in German, English abstract].
11. Baumgart DC and Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007; 369: 1641-1657.
12. Fiorino G, Fries W, De La Rue SA, et al. New drug delivery systems in inflammatory bowel disease: MMXTM and tailored delivery to the gut. Curr Med Chem 2010; 17: 1851-1857.
13. Brunner M, Ziegler S, Di Stefano AF, et al. Gastrointestinal transit, release and plasma pharmacokinetics of a new oral budesonide formulation. Br J Clin Pharmacol 2006; 61: 31-38.
14. Sandborn WJ, Travis S, Moro L, et al. Oncedaily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I Study. Gastroenterology 2012; 143: 1218-1226.
15. Travis S, Danese S, Kupcinskas L, et al. Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. Gut; Epub ahead of print 22 February 2013, doi:10.1136/gutjnl-2012-304258.
16. Sandborn WJ, Travis S, Bala N, et al. Induction of clinical and endoscopic remission of mild to moderately active ulcerative colitis with Budesonide MMX® 9 mg: analysis of pooled data from two phase 3 studies. Am J Gastroenterol 2011; 106(Suppl 2): S-485.
17. Seidegård J, Randvall G, Nyberg L, et al. Grapefruit juice interaction with oral budesonide: equal effect on immediate-release and delayed-release formulations. Pharmazie 2009; 64: 461-465.